Drug intelligence / Profile preview

AmnioHeal Plus

Development stage: Unknown
Lead developer: Tides Medical
Administration: Topical

Overview

AmnioHeal Plus is a dual-layer amniotic tissue allograft developed by Tides Medical for wound care and surgical applications. It is processed from donated human placental tissue and maintained in an ambient state. The graft acts as a biological scaffold and a source of endogenous growth factors, cytokines, and extracellular matrix proteins, which are essential for tissue regeneration and wound healing. It is specifically used for treating chronic wounds such as diabetic foot ulcers, pressure ulcers, and venous stasis ulcers, as well as burns and surgical sites.

Brand names: AmnioHeal Plus

Targets

IL10 (Interleukin-10)

Beyond the preview

Go deeper on AmnioHeal Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmnioHeal Plus.

Explore the full profile